Clinical Trial Update: A Study to Determine the Safety and Efficacy of NT-501 With MHFM [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating NT-501 with MHFM for Macular Telangiectasia Type 2 is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Macular Telangiectasia Type

Drugs mentioned

• NT-501 with MHFM (NT-501)

Snippet

Sponsor: Neurotech Pharmaceuticals | Conditions: Macular Telangiectasia Type 2 | Phase 3 | Status: ACTIVE_NOT_RECRUITING